Introduction :Interleukin-6 (IL-6) encodes a cytokine protein, which causes inflammation, maintains immune homeostasis and plays an essential role in oral pathogenesis. The aim of this study was to evaluate the association between IL-6 (−174 and −572) G/C promoter gene polymorphismsand risk of Oral pre cancer and cancer among Indians.
INTRODUCTION
Interleukin-6 (IL-6)is a proinflammatory cytokine produced by a number of cell types including cancer cells 1 . Elevated levels of circulating IL-6 have been seen in many clinical situations characterized by tissue injury, such as trauma (including major surgery),ischemia,burns,malignant conditions,exposure to toxins and aseptic irritants,immune hypersensitivity reactions,inflammatory,infectious and autoimmune diseases 2 . IL-6, also known as B cell differentiation factor, is an immune regulatory cytokine, involved in the regulation of various cellular functions (angiogenesis, apoptosis, proliferation, differentiation and regulation of immune response). As a growth factor IL-6 plays a significant role in cell differentiation and is believed to be involved in tumor progression 3 . High IL-6 levels have been shown to correlate with poor prognosis and high mortality in prostate and colorectal cancer patients. Oral squamous cell carcinoma (OSCC) is a common malignant tumor of the oral cavity and has a high incidence with poor prognosis in India, 6, 7 OSCC is one of the major cause of cancer-related deaths. In India over the world, It is predominant in Indian males 8, 9 . OSCC is multistep progression which is influenced by several environmental factors, such as tobaccochewing, smoking and alcohol consumption and further alteration in genes, such as tumor suppressor genes and oncogenes 10, 11 . Several studies have observed that the common polymorphisms in angiogenesis, inflammation and thrombosis-related genes, are associated with increased risk oforal cancer and other cancerous condition [8] [9] [10] [11] [12] . One such factor, related with both thrombosis and malignancy, is interleukin-6 (IL-6). [13] [14] [15] [16] [17] IL-6 may also have an essential role in the growth and differentiation of malignant tumors. 18, 19 IL-6 is a multifunctional cytokine of Th2 type which has both, pro-inflammatory and anti-inflammatory cytokine activities 12 . It is a glycoprotein which consists of184 amino acids and has a molecular weight of 26 kDa 13 . It is involved in tumor growth,differentiation of malignant cancer cells and microenvironment immune-modulation. 20, 14 These properties are the result of enhanced neo-angiogenesis, inhibition of cancercell apoptosis and acquired cell resistance 16 . IL-6 is secreted by T cells, which iscapable of stimulating immune responses, including responses to tumors. The IL-6 gene is located on chromosome 7p21 and the SNPs at the 5′ flanking region of the IL-6 promoter, to be identified as IL-6−174 and −572 (15) . IL-6 (−174) G/C genepolymorphism is one of the most frequentlystudied polymorphisms. IL-6 (−174) G/C gene polymorphism alters the expression of IL-6 gene. The genotypes GC, CC and allele C of IL-6 (−174) G/C gene polymorphism are mutated and increased the risk of oral cancer 21 . The previous study shown that the IL-6 (−174) G/C gene polymorphism was significantly associated with some cancers other also such of breast, ovarian, prostatic, gastric, cervical and colorectal cancer [22] [23] [24] [25] [26] . The IL-6 (−572) G allele is also associated with increased level of IL-6 protein in serumthan C/C allele and is significantly associated with the risk of oral cancer 27, 28 . On the contrary IL-6 (−174 and −572) C/G gene polymorphisms are not associatedwith the risk of gastric cancer, moreover they lower the risk of bladder cancer 29, 30 .Since the association between IL-6 (−174G/C and−572G/C) gene polymorphismwith OSCC in the Indian population has yet not been studied, we investigated the role of IL-6 promoter (−174) G/C and (−572) G/C gene polymorphisms in pathogenesis of OSCC in Indian population.
Our study have focus the association between IL-6 (174G/C and 572G/C). The study focus specifically the rate of IL-6 promoter with (-174 G/C and -572 G/C) genome polymorphism and their pathogensis in oral cancer patients. The previous study with IL-6 (-174 G/C and -572 G/C) focus in other cancer condition. Our study have also assess the relationship between IL-6 174 G/C promoter polymorphism and IL-6 572 G/C in North Indian population.
MATERIALS AND METHODS

Collection of samples
The study comprised with 250 patients sample. All the subject samples were histopathologically confirmed oral pre cancer and cancer who were registered in the department of Oral Pathology & Microbiology and department of Radiotherapy, King George's Medical University, Lucknow and 250 healthy controls. Informed written consent was obtained from all subjects. The research study is ethically approved by the Institutional ethics committee K.G.M.U, Lucknow, India.
Extraction of genomic DNA and molecular analyses
Venous blood samples were collected in EDTA tubes and stored at −80 °C, till DNA extraction. Genomic DNA extraction from blood samples was carried out by salting out method 31 .
Genotyping of IL-6 (−174) G/C gene polymorphism
The IL-6 (-174) G/C polymorphism was analysed by the polymerase chain reaction (PCR) followed by restriction fragment length polymorphism. Genomic DNA was amplified using the standard PCR conditions: 94˚C for 4 min, 35 cycles at 94˚C for 30 s, 61˚C for 30 s, 72˚C for 45 s, and finally 72˚C for 10 min. The primers used for amplification of the IL-6 (-174) G/C gene polymorphisms were as follows: forward primer 5'-GGAGTCACACACTCCACCT-3'and reverse primer 5'-GTGGGGCTGATTGGAAACC-3'. Amplification success of samples was monitored on 2% agarose gel by Gel electrophoresis. There after the PCR products were subjected to digestion by N1aIII enzyme to screen for the G174C polymorphism.
Genotyping of IL-6 (−572) G/C gene polymorphism
The IL-6 (-572) G/C polymorphism was analysed by the polymerase chain reaction (PCR) followed by restriction fragment length polymorphism. Genomic DNA was amplified using the following PCR conditions: 94˚C for 4 min, 35 cycles at 94˚C for 30 s, 61˚C for 30 s, 72˚C for 45 s, and finally 72˚C for 10 min. The primers used for amplification of the IL-6 (-572) G/C gene polymorphisms were as follows: forward primer 5'-GGAGACGCCTTGAAGTAACTGC-3'and reverse primer 5'-GAGTTTCCTCTGACTCCATCGCAG-3'. Amplification success of samples was monitored on 2% agarose gel by Gel electrophoresis. There after the PCR products were subjected to digestion by DdeI enzyme to screen for the G572C polymorphism.
STATISTICAL ANALYSIS:
The statistical significance in this study was evaluated by Chi-square test. Odds ratio (OR) was calculated as an estimate of relative risk of having disease according to the relative frequency of different genotypes among the cases as well as the controls. ORs are given with 95% confidence interval (CI).
RESULTS
The demographic profile evaluated included age, gender, relative environmental risk factors and tumor staging which may contribute the progression of Oral pre cancer and cancer are shown in (Table 1) .
The genotype and allele frequencies of the IL-6 (−174) G/C and IL-6 (−572) G/C gene polymorphisms among the controls and Oral pre cancer and cancer patients are shown in (Table 2 ). The frequencies of the GG, GC and CC genotypes of IL-6 (−174G/C) were 54.80%, 37.20% and 8.00% in the Oral pre cancer and cancer patients and 68.80%, 27.20% and 4.00% in controls, respectively. On the other hand the allele frequencies of theG and C were 73.40% and (Table 2) .Therewere significant differences in the GC genotype and C allele frequencies of the IL-6 (−174) Table 2 ).
The genotypeGC and C allele frequencies of the IL-6 (−174)G/C gene polymorphismwith oral submucous fibrosis and malignancy, were significantly associated with oral pre cancer and cancer (Table 3 ).
The frequencies of the GG, GC and CC genotypes of IL-6 (−572) G/C were 26.80%, 64.00% and 9.20% in theOral pre cancer and cancer patients and 30.00%, 62.00% and 8.00% in controls, respectively. On the other hand the allele frequenciesof the G and C were 58.80% and 41.20% in the Oral pre cancer and cancer patients and 61.00% and 39.00% in controls, respectively( Table 2 ). The genotypes and allele frequencies of the IL-6 (−572) G/C were not significantly different betweencontrols and Oral pre cancer and cancer patients.
The correlation between genotypes and allele frequencies of IL-6 (−174) G/C and (−572) G/C gene polymorphisms with oral submucous fibrosis, lichen planus, leukoplakia, malignancy susceptibility, is shown in (Table 3 ).
The genotype frequencies of GG, GC and CC of the IL-6 (−174) G/C gene polymorphisms were significantly associated with the development oforal pre cancer and cancer as compared with controls (Table 2) . However the GC, GC, CC genotype of the In the case of G174C polymorphism, an undigested 533 bp band showed wild-type GG genotype, while two bands of 482 and 51 bp confirmed mutant CC genotype and three bands of 533, 482 and 51 bp were detected in the heterozygous GC genotype (Figure 1 ).
Followed by this forward and reverse sequence of IL-6(-174G/C) were also observed and confirmed the nucleotide sequence in given sample.
In the case of G572C polymorphism, an undigested 163 bp band showed wild-type GG genotype, while two bands of 91 and 72 bp confirmed mutant CC genotype and three bands of 163, 91 and 72 bp were detected in the heterozygous GC genotype (Figure 4 ).
Followed by this forward and reverse sequence of IL-6(-572G/C) were also observed and confirmed the nucleotide sequence in given sample.
DISCUSSION
In the present study, we found that the promoter (−174) GC genotype is significantly associated with increased risk of oral pre cancer and cancer. Moreover, the −174 C allele was also associated with a high risk for development of Oral pre cancer and cancer. The genotype and allele frequencies of IL-6 (−572) G/C were not significantly associated with the risk of Oral pre cancer and cancer. The reported observations of various studies, about the association of IL-6 gene polymorphism with various cancers, are variable. A previous study by 21 reported that the IL-6 gene polymorphism is strongly correlatedwith increased risk for oral cancer by affecting IL-6 gene expression.The GC heterozygotes and CC homozygoteswere significantly associatedwith the development and progression of oral cancer 21 . Our finding are also supported by De
Michael et al 23 and Landi et al 24 , who reported that the genotypes (GC, CC) and allele C frequencies of IL-6 (−174) G/C were significantly associated with increased risk for breast and colorectal cancers 23, 24 . Several previous studies have shown that the elevated level of IL-6 protein in serum is present in many cancers (OSCC, breast, prostate, ovarian, gastric, colorectal and cervical cancers), in which the C allele of promoter (−174G/C) gene polymorphismwas found to be associated with increased production of IL-6 protein and increase the risk of cancers 32, 22, 33, 34, 35, 36 . On the contrary, several studies reported that the IL-6 (−174) G/C gene polymorphism was not significant associatedwith many cancers (breast, prostate, colorectal, lung and gastric cancer) lymphoma, melanoma and multiple myeloma 29, 37 . Individuals with the C allele of IL-6 (−572) G/C gene polymorphism and the GG genotype for the IL-6 (−174) G/C gene polymorphismwere associatedwith decreased risk of colon cancer, but with an increased risk of rectal cancer 25 . Liang et al. (2013) reported that the C allele at (−572) locus of IL-6 genepolymorphism was significantly associated with lung cancer 38 . Yin et al. (2012) suggested that the IL-6 (−174 C/G and−572 C/G) gene polymorphisms were not associated with the risk of gastric cancer 30 .
The immune response to inflammationfrequently plays an important role in the pathogenesis of a tumor 39 . Genetic alterationalso plays a significant role in the inflammatory response, which may be associated with the risk ofdevelopment of various cancers, including the oral cancer 39 . IL-6 is an immuneregulatorycytokine with biological functions of pro-inflammation, anti-inflammation and angiogenesis.These responses are triggered by activation of the JAK tyrosine kinase family and then further stimulated bythe MAPK, PI3K, or STAT 43 . IL-6 (−174G/C) promoter SNP is a crucial mediator of the Th2 response, that has been associatedwithincreased IL-6 production 39 . During the inflammation, the C allele of IL-6 (−174) G/C genepolymorphism elevates the level of IL-6 protein 44, 45 . Inaddition, several studies have reported that IL-6 protein level increase with the development and progression of tumors, including oral cancer 23, 46 and this increased level of IL-6 proteinwas associatedwith poor prognosis and highmortalityin various cancers 5, 47 .
In our study the genotypes and allele frequencies of IL-6 (−174 and−572) G/C gene polymorphism were not associated with environmental factors (tobacco chewing, smoking and alcohol consumption) and tumor progression. These results are similar to that of 48 ,who showed that IL-6 (−174) G/C gene polymorphism was not associated with either breast cancer risk or severity and prognosis, as assessed by tumor grade and lymph node status Balasubramaniam et al 48 It can be concluded that the present study provides evidence of the correlation between IL-6 (−174) G/C gene polymorphism with risk of OSCC. The GC genotype and C allele are significantly associated with the risk of OSCC, whereas IL-6 (−572) G/C polymorphism is not associated with OSCC. Moreover related environmental factors and gene interactions are not associated with pathogenesis of OSCC. IL-6(−174 and −572) promoter gene polymorphisms are not significantly associated with progression of OSCC. Genotyping in the our study showed that unlike (-174G/C and -572G/C)polymorphism was significantly associated in our study samples. The gene IL-6 174G/C genotypes showed in support at the meta genomic study in our sample and prevalence of GC genotype "c" allele and GC genotype of IL-6 174G/C were found significantly associated for oral cancer patients as frequently is higher in controls. There were no significant association of IL-572G/C genotype allele were observed in IL-6-572G/C polymorphism. Our statically data suggest that IL-6 gene polymorphism play an important role to determine the progression and susceptibility of oral pre cancer and oral cancer. This study given a prominent lead to contribution of IL-6 gene with the development of OSCC patients in North Indian population.This finding suggests that IL-6 may be used as a diagnostic marker for effective management of OSCCin future, though further studies with larger sample sizes will be necessary to confirm this. 
